Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

Abstract Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resistant chronic migraine (CM) is sparse.  Methods Thi...

Full description

Bibliographic Details
Main Authors: Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Format: Article
Language:English
Published: BMC 2022-11-01
Series:The Journal of Headache and Pain
Subjects:
Erenumab
Chronic migraine
Resistant migraine
CGRP
Monoclonal antibodies
Online Access:https://doi.org/10.1186/s10194-022-01507-8

Internet

https://doi.org/10.1186/s10194-022-01507-8

Similar Items